Dr. McDonald on the Next Step for Angiogenesis Inhibitors

Donald M. McDonald, MD, PhD
Published: Tuesday, Sep 13, 2011

Donald M. McDonald, MD, PhD, a professor in the Department of Anatomy and an investigator in the Cardiovascular Research Institute at the University of California, San Francisco Comprehensive Cancer Center, explains that in the early stages of treatment with angiogenesis inhibitors the sky was believed to be the limit.

It was believed that blocking angiogenesis could stop tumor growth and keep tumors in a dormant state. Some cancers see great benefit, but limitations have become evident, particularly in breast cancer. Overcoming the limitations of inhibiting angiogenesis will be the next research step to take.

Donald M. McDonald, MD, PhD, a professor in the Department of Anatomy and an investigator in the Cardiovascular Research Institute at the University of California, San Francisco Comprehensive Cancer Center, explains that in the early stages of treatment with angiogenesis inhibitors the sky was believed to be the limit.

It was believed that blocking angiogenesis could stop tumor growth and keep tumors in a dormant state. Some cancers see great benefit, but limitations have become evident, particularly in breast cancer. Overcoming the limitations of inhibiting angiogenesis will be the next research step to take.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x